Summit Therapeutics Inc.
SMMT
NASDAQ·Healthcare·Biotechnology·Mkt cap $11.6B
$14.60
▲ +3.11%
P/E
-28.08
Mkt Cap
$11.6B
52-Wk Range
$12.07–$29.23
52-Week Range
$12.07 - $29.23
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 37.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta -1.2).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-3.1% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying SMMT right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 19, 2026
JUL 23, 2026
Reported EPS of -$0.28 vs -$0.27 consensus (-2.0% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.0%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$0
$0
Margins · last 2Q
No margin history available.
Wall Street consensus
6 analysts · 33% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
33%
Hold
67%
Sell
0%
Median Price Target
—
Latest: Guggenheim · Aug 26, 2026
vs Industry
How SMMT stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.